PATRIMONIO MUEBLE E INTANGIBLE
2.2.6 Patrimonio natural en FERROL- ORTEGAL Fuentes:
2.2.6.3 Espacios Naturales:
Abbreviation Definition
AIP Aryl Hydrocarbon Receptor Interacting Protein ARID1A AT-Rich Interaction Domain 1A
ARID1B AT-Rich Interaction Domain 1B
ARID2 AT-Rich Interaction Domain 2
ASXL1 ASXL Transcriptional Regulator 1
ATM ATM Serine/Threonine Kinase
AXL AXL Receptor Tyrosine Kinase
BRCA1 BRCA1, DNA Repair Associated
BRCA2 BRCA2, DNA Repair Associated
BRD4 Bromodomain-Containing Protein 4
CABLES1 Cdk5 and Abl Enzyme Substrate 1
CCND2 Cyclin D2
CCND3 Cyclin D3
CDK4 Cyclin Dependent Kinase 4
CDKN1A Cyclin Dependent Kinase Inhibitor 1A CDKN1B Cyclin Dependent Kinase Inhibitor 1B
CREBBP CREB Binding Protein
CRHR1 Corticotropin Releasing Hormone Receptor 1
EGFR Epidermal Growth Factor Receptor
EP300 E1A Binding Protein P300
ERBB3 Erb-B2 Receptor Tyrosine Kinase 3 ERBB4 Erb-B2 Receptor Tyrosine Kinase 4
ETV6 ETS Variant 6
FANCA Fanconi Anemia Complementation Group A FANCE Fanconi Anemia Complementation Group E FBXW7 F-Box and WD Repeat Domain Containing 7
GATA3 GATA Binding Protein 3
GLI1 GLI Family Zinc Finger 1
GLI2 GLI Family Zinc Finger 2
GLI3 GLI Family Zinc Finger 3
GNAS GNAS Complex Locus
GPR101 G Protein-Coupled Receptor 101
HNF1A HNF1 Homeobox A
KAT6A Lysine Acetyltransferase 6A
KMT2D Lysine Methyltransferase 2D
KRAS Kirsten Rat Sarcoma 2 Viral Oncogene Homolog
MDM2 Mouse Double Minute 2 Homolog
MEN1 Multiple Endocrine Neoplasia 1
NF2 Neurofibromatosis Type 2
NOTCH1 Neurogenic Locus Notch Homolog Protein 1 NOTCH2 Neurogenic Locus Notch Homolog Protein 2
PCV3 Porcine Circovirus 3
PIK3CA Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha
PIM1 Proto-Oncogene Serine/Threonine Protein Kinase
POMC Proopiomelanocortin
PRKAR1A Protein Kinase cAMP-Dependent Regulatory Type 1 Alpha PRKDC Protein Kinase DNA-Activated Catalytic Subunit
PTPN11 Protein Tyrosine Phosphatase Non-Receptor Type 11
RET Ret Proto-Oncogene
SDHx Succinate Dehydrogenase Complex Iron Sulfur
SH2B3 SH2B Adaptro Protein 3
SMARCA4 SWI/SNF Related Matrix Associated Actin Dependent Regulator of Chromatin Subfamily A Member 4
SMARCB1 SWI/SNF Related Matrix Associated Actin Dependent Regulator of Chromatin Subfamily B Member 1
SSTR1 Somatostatin Receptor 1
SSTR2 Somatostatin Receptor 2
STAT6 Signal Transducer and Activator of Transcription 6
TP53 Tumor Protein P53
TP53BP1 Tumor Protein P53 Binding Protein 1 U2AF1 U2 Small Nuclear RNA Auxiliary Factor 1 USP8 Ubiquitin Specific Peptidase 8
V1BR Vasopressin Receptor 1B
WT1 Wilms Tumor Protein
REFERENCES
1. Bi, W. L., Greenwald, N. F., Ramkissoon, S. H., Abedalthagafi, M., Coy, S. M., Ligon, K. L., … Dunn, I. F. (2017). Clinical Identification of Oncogenic
Drivers and Copy-Number Alterations in Pituitary Tumors. Endocrinology, 158(7), 2284–2291. https://doi.org/10.1210/en.2016-1967
2. Gittleman, H., Ostrom, Q. T., Farah, P. D., Ondracek, A., Chen, Y., Wolinsky, Y., … Barnholtz-Sloan, J. S. (2014). Descriptive epidemiology of pituitary tumors in the United States, 2004–2009. Journal of Neurosurgery, 121(3), 527–535. https://doi.org/10.3171/2014.5.JNS131819
3. Radhakrishnan, K., Mokri, B., Parisi, J. E., O’Fallon, W. M., Sunku, J., &
Kurland, L. T. (1995). The trends in incidence of primary brain tumors in the population of rochester, minnesota. Annals of Neurology, 37(1), 67–73.
https://doi.org/10.1002/ana.410370113
4. Saeger, W., Ludecke, D. K., Buchfelder, M., Fahlbusch, R., Quabbe, H.-J., &
Petersenn, S. (2007). Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. European Journal of Endocrinology, 156(2), 203–216.
https://doi.org/https://doi.org/10.1530/eje.1.02326
5. Mete, O., & Lopes, M. B. (2017). Overview of the 2017 WHO Classification of Pituitary Tumors. Endocrine Pathology, 28(3), 228–243.
https://doi.org/10.1007/s12022-017-9498-z
6. LIU, J. H., KAZER, R. R., & RASMUSSEN, D. D. (1987). Characterization of the Twenty-Four Hour Secretion Patterns of Adrenocorticotropin and Cortisol in Normal Women and Patients with Cushing’s Disease*. The Journal of Clinical Endocrinology & Metabolism, 64(5), 1027–1035.
https://doi.org/10.1210/jcem-64-5-1027
7. Kairys, N., & Schwell, A. (2018). Cushing Disease. StatPearls. StatPearls Publishing. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/28846264 8. Dekkers, O. M., Biermasz, N. R., Pereira, A. M., Roelfsema, F., van Aken, M.
O., Voormolen, J. H. C., & Romijn, J. A. (2007). Mortality in Patients Treated for Cushing’s Disease Is Increased, Compared with Patients Treated for Nonfunctioning Pituitary Macroadenoma. The Journal of Clinical
Endocrinology & Metabolism, 92(3), 976–981.
https://doi.org/10.1210/jc.2006-2112
9. Reincke, M., Sbiera, S., Hayakawa, A., Theodoropoulou, M., Osswald, A., Beuschlein, F., … Komada, M. (2015). Mutations in the deubiquitinase gene USP8 cause Cushing’s disease. Nature Genetics, 47(1), 31–38.
https://doi.org/10.1038/ng.3166
10. Nieman, L. K., Biller, B. M. K., Findling, J. W., Newell-Price, J., Savage, M.
O., Stewart, P. M., & Montori, V. M. (2008). The Diagnosis of Cushing’s Syndrome: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism, 93(5), 1526–1540.
https://doi.org/10.1210/jc.2008-0125
11. Nieman, L. K., Biller, B. M. K., Findling, J. W., Murad, M. H., Newell-Price, J., Savage, M. O., & Tabarin, A. (2015). Treatment of Cushing’s Syndrome: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical
Endocrinology & Metabolism, 100(8), 2807–2831.
https://doi.org/10.1210/jc.2015-1818
12. Kaiser, U. B. (2015). Cushing’s disease: towards precision medicine. Cell Research, 25(6), 649–650. https://doi.org/10.1038/cr.2015.53
13. Perez-Rivas, L. G., & Reincke, M. (2016). Genetics of Cushing’s disease: an update. Journal of Endocrinological Investigation, 39(1), 29–35.
https://doi.org/10.1007/s40618-015-0353-0
14. Albani, A., Pérez-Rivas, L. G., Dimopoulou, C., Zopp, S., Colón-Bolea, P., Roeber, S., … Theodoropoulou, M. (2018). The USP8 mutational status may predict long-term remission in patients with Cushing’s disease. Clinical Endocrinology, 89(4), 454–458. https://doi.org/10.1111/cen.13802 15. Theodoropoulou, M., Reincke, M., Fassnacht, M., & Komada, M. (2015).
Decoding the genetic basis of cushing’s disease: Usp8 in the spotlight.
European Journal of Endocrinology, 173(4), M73–M83.
https://doi.org/10.1530/EJE-15-0320
16. Ben-Shlomo, A., & Cooper, O. (2018). Silent corticotroph adenomas, 21, 183–193. https://doi.org/10.1007/s11102-018-0864-8
17. Kim, D., Ku, C. R., Park, S. H., Moon, J. H., Kim, E. H., Kim, S. H., & Lee, E.
J. (2018). Clinical Parameters to Distinguish Silent Corticotroph Adenomas from Other Nonfunctioning Pituitary Adenomas. World Neurosurgery, 115, e464–e471. https://doi.org/10.1016/J.WNEU.2018.04.070
18. Raverot, G., Wierinckx, A., Jouanneau, E., Auger, C., Borson-Chazot, F.,
characterization of pituitary ACTH adenomas without (silent corticotroph adenomas) and with Cushing’s disease. European Journal of Endocrinology, 163(1), 35–43. https://doi.org/https://doi.org/10.1530/EJE-10-0076
19. Horvath, E., Kovacs, K., & Scheithauer, B. (1999). Pituitary Hyperplasia.
Pituitary, 1(3/4), 169–179. https://doi.org/10.1023/A:1009952930425
20. Meij, B. P., Lopes, M. B. S., Vance, M. L., Thorner, M. O., & Laws, Jr., E. R.
(2000). Double Pituitary Lesions in Three Patients with Cushing’s Disease.
Pituitary, 3(3), 159–168. https://doi.org/10.1023/A:1011499609096
21. Haap, M., Gallwitz, B., Meyermann, R., & Mittelbronn, M. (2008). Cushing’s Disease Associated with both Pituitary Microadenoma and Corticotroph Hyperplasia. Experimental and Clinical Endocrinology & Diabetes, 117(06), 289–293. https://doi.org/10.1055/s-0028-1085997
22. Gomes, A. C., Neto, L. L., Tortosa, F., Carvalho, M. R., Barreiros, E., Barreiros, L., … Bugalho, M. J. (2017). Cushing’s disease: is there a
Continuum from corticotroph hyperplasia to adenoma? Endocrine Abstracts.
https://doi.org/10.1530/endoabs.49.EP974
23. Streuli, R., Krull, I., Brändle, M., Kolb, W., Stalla, G., Theodoropoulou, M., … Bilz, S. (2017). A rare case of an ACTH/CRH co-secreting midgut
neuroendocrine tumor mimicking Cushing’s disease. Endocrinology, Diabetes & Metabolism Case Reports, 2017. https://doi.org/10.1530/EDM-17-0058
24. Metzker, M. L. (2010). Sequencing technologies — the next generation.
Nature Reviews Genetics, 11(1), 31–46. https://doi.org/10.1038/nrg2626 25. Deans, Z. C., Costa, J. L., Cree, I., Dequeker, E., Edsjö, A., Henderson, S.,
… IQN Path ASBL, O. behalf of I. P. (2017). Integration of next-generation sequencing in clinical diagnostic molecular pathology laboratories for analysis of solid tumours; an expert opinion on behalf of IQN Path ASBL.
Virchows Archiv, 470(1), 5–20. https://doi.org/10.1007/s00428-016-2025-7 26. Bi, W. L., Horowitz, P., Greenwald, N. F., Abedalthagafi, M., Agarwalla, P. K.,
Gibson, W. J., … Dunn, I. F. (2017). Landscape of Genomic Alterations in Pituitary Adenomas. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 23(7), 1841–1851.
https://doi.org/10.1158/1078-0432.CCR-16-0790
27. Einaga, N., Yoshida, A., Noda, H., Suemitsu, M., Nakayama, Y., Sakurada, A., … Esumi, M. (2017). Assessment of the quality of DNA from various
formalin-fixed paraffin-embedded (FFPE) tissues and the use of this DNA for next-generation sequencing (NGS) with no artifactual mutation. PloS One, 12(5), e0176280. https://doi.org/10.1371/journal.pone.0176280
28. ONCOPANEL (POPv3) TEST INFORMATION. (n.d.). Retrieved from
https://researchcores.partners.org/data/wiki_pages/97/POPv3_TEST_INFO RMATION.pdf
29. Garcia, E. P., Minkovsky, A., Jia, Y., Ducar, M. D., Shivdasani, P., Gong, X.,
… Dong, F. (2017). Validation of OncoPanel A Targeted Next-Generation Sequencing Assay for the Detection of Somatic Variants in Cancer. Arch Pathol Lab Med, 141, 751–758. https://doi.org/10.5858/arpa.2016-0527-OA 30. Sholl, L. M., Do, K., Shivdasani, P., Cerami, E., Dubuc, A. M., Kuo, F. C., …
MacConaill, L. E. (2016). Institutional implementation of clinical tumor profiling on an unselected cancer population. JCI Insight, 1(19), e87062.
https://doi.org/10.1172/jci.insight.87062
31. Frampton, G. M., Fichtenholtz, A., Otto, G. A., Wang, K., Downing, S. R., He, J., … Yelensky, R. (2013). Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nature Biotechnology, 31(11), 1023–1031. https://doi.org/10.1038/nbt.2696
32. ONCOPANEL TEST INFORMATION. (2014). Retrieved from
https://researchcores.partners.org/data/wiki_pages/97/Oncopanel_POPv2_T estDescription_9_4_14.pdf
33. Iacovazzo, D., Hernández-Ramírez, L. C., & Korbonits, M. (2017). Sporadic pituitary adenomas: the role of germline mutations and recommendations for genetic screening. Expert Review of Endocrinology & Metabolism, 12(2), 143–153. https://doi.org/10.1080/17446651.2017.1306439
34. Pepe, S., Pepe, S., Korbonits, M., & Iacovazzo, D. (2019). Germline and mosaic mutations causing pituitary tumours: genetic and molecular aspects.
Journal of Endocrinology, 240(2), R21–R45. https://doi.org/10.1530/JOE-18-0446
35. Caimari, F., & Korbonits, M. (2016). Novel Genetic Causes of Pituitary Adenomas. Clinical Cancer Research, 22(20), 5030–5042.
https://doi.org/10.1158/1078-0432.CCR-16-0452
36. Salomon, M. P., Wang, X., Marzese, D. M., Hsu, S. C., Nelson, N., Zhang, X., … Hoon, D. S. B. (2018). The Epigenomic Landscape of Pituitary
Acromegaly, Cushing’s Disease and Endocrine-Inactive Subtypes. Clinical Cancer Research, 24(17), 4126–4136.
https://doi.org/10.1158/1078-0432.CCR-17-2206
37. Edwards, T. J., Sherr, E. H., Barkovich, A. J., & Richards, L. J. (2016). Reply:
ARID1B mutations are the major genetic cause of corpus callosum anomalies in patients with intellectual disability. Brain, 139(11), e65–e65.
https://doi.org/10.1093/brain/aww171
38. Helming, K. C., Wang, X., Wilson, B. G., Vazquez, F., Haswell, J. R., Manchester, H. E., … Roberts, C. W. M. (2014). ARID1B is a specific vulnerability in ARID1A-mutant cancers. Nature Medicine, 20(3), 251–254.
https://doi.org/10.1038/nm.3480
39 Celen, C., Chuang, J.-C., Luo, X., Nijem, N., Walker, A. K., Chen, F., … Zhu, H. (2017). Arid1b haploinsufficient mice reveal neuropsychiatric phenotypes and reversible causes of growth impairment. ELife, 6.
https://doi.org/10.7554/ELIFE.25730
40. Forbes, S. A., Beare, D., Boutselakis, H., Bamford, S., Bindal, N., Tate, J., … Campbell, P. J. (2017). COSMIC: somatic cancer genetics at
high-resolution. Nucleic Acids Research, 45(D1), D777–D783.
https://doi.org/10.1093/nar/gkw1121
41. Li, X. S., Trojer, P., Matsumura, T., Treisman, J. E., & Tanese, N. (2010).
Mammalian SWI/SNF--a subunit BAF250/ARID1 is an E3 ubiquitin ligase that targets histone H2B. Molecular and Cellular Biology, 30(7), 1673–1688.
https://doi.org/10.1128/MCB.00540-09
42. Tomlinson, I. P., Webb, E., Carvajal-Carmona, L., Broderick, P., Howarth, K., Pittman, A. M., … Houlston, R. S. (2008). A genome-wide association study identifies colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3. Nature Genetics, 40(5), 623–630. https://doi.org/10.1038/ng.111 43. Álvaro, E., Cano, J. M., García, J. L., Brandáriz, L., Olmedillas-López, S.,
Arriba, M., … Perea, J. (2019). Clinical and Molecular Comparative Study of Colorectal Cancer Based on Age-of-onset and Tumor Location: Two Main Criteria for Subclassifying Colorectal Cancer. International Journal of Molecular Sciences, 20(4), 968. https://doi.org/10.3390/ijms20040968 44. Lichtner, P., König, R., Hasegawa, T., Van Esch, H., Meitinger, T., &
Schuffenhauer, S. (2000). An HDR (hypoparathyroidism, deafness, renal dysplasia) syndrome locus maps distal to the DiGeorge syndrome region on
10p13/14. Journal of Medical Genetics, 37(1), 33–37.
https://doi.org/10.1136/JMG.37.1.33
45. Katase, N., Gunduz, M., Beder, L. B., Gunduz, E., Sheikh Ali, M. Al, Tamamura, R., … Nagatsuka, H. (2010). Frequent Allelic Loss of Dkk-1 Locus (10q11.2) is Related with Low Distant Metastasis and Better Prognosis in Head and Neck Squamous Cell Carcinomas. Cancer
Investigation, 28(1), 103–110. https://doi.org/10.3109/07357900903095680 46. Matsuo, K., Tang, S.-H., & Fagin, J. A. (1991). Allelotype of Human Thyroid
Tumors: Loss of Chromosome 11q13 Sequences in Follicular Neoplasms.
Molecular Endocrinology, 5(12), 1873–1879. https://doi.org/10.1210/mend-5-12-1873
47. Chambers, T. J. G., Giles, A., Brabant, G., & Davis, J. R. E. (2013). Wnt signalling in pituitary development and tumorigenesis. Endocrine-Related Cancer. https://doi.org/10.1530/erc-13-0005
48. Yuan, Z., Claros, C. S., Suzuki, M., Maggi, E. C., Kaner, J. D., Kinstlinger, N.,
… Libutti, S. K. (2016). Loss of MEN1 activates DNMT1 implicating DNA hypermethylation as a driver of MEN1 tumorigenesis. Oncotarget, 7(11), 12633. https://doi.org/10.18632/ONCOTARGET.7279
49. Murakumo, Y., Jijiwa, M., Asai, N., Ichihara, M., & Takahashi, M. (2006). RET and neuroendocrine tumors. Pituitary, 9(3), 179–192.
https://doi.org/10.1007/s11102-006-0263-4
50. Mete, O., Kefeli, M., Çalışkan, S., & Asa, S. L. (2019). GATA3 immunoreactivity expands the transcription factor profile of pituitary neuroendocrine tumors. Modern Pathology, 32(4), 484–489.
https://doi.org/10.1038/s41379-018-0167-7
51. Savelieva, E., Belair, C. D., Newton, M. A., DeVries, S., Gray, J. W., Waldman, F., & Reznikoff, C. A. (1997). 20q gain associates with
immortalization: 20q13.2 amplification correlates with genome instability in human papillomavirus 16 E7 transformed human uroepithelial cells.
Oncogene, 14(5), 551–560. https://doi.org/10.1038/sj.onc.1200868
52. Aust, D. E., Muders, M., Köhler, A., Schmidt, M., Diebold, J., Müller, C., … Baretton, G. B. (2004). Prognostic relevance of 20q13 gains in sporadic colorectal cancers: a FISH analysis. Scandinavian Journal of
Gastroenterology, 39(8), 766–772.
https://doi.org/10.1080/00365520410003191
53. Wang, D., Zhu, Z.-Z., Jiang, H., Zhu, J., Cong, W.-M., Wen, B.-J., … Liu, S.-F. (2015). Multiple genes identified as targets for 20q13.12–13.33 gain contributing to unfavorable clinical outcomes in patients with hepatocellular carcinoma. Hepatology International, 9(3), 438–446.
https://doi.org/10.1007/s12072-015-9642-0
54. Mekkawy, M. K., Mazen, I. M., Kamel, A. K., Vater, I., & Zaki, M. S. (2016).
Genotype/phenotype correlation in a female patient with 21q22.3 and
12p13.33 duplications. American Journal of Medical Genetics Part A, 170(4), 1050–1058. https://doi.org/10.1002/ajmg.a.37523
55. Braddock, S. R., South, S. T., Schiffman, J. D., Longhurst, M., Rowe, L. R., &
Carey, J. C. (2016). Braddock-Carey syndrome: A 21q22 contiguous gene syndrome encompassing RUNX1. American Journal of Medical Genetics Part A, 170(10), 2580–2586. https://doi.org/10.1002/ajmg.a.37870
56. Weber, S., Haferlach, C., Jeromin, S., Nadarajah, N., Dicker, F., Noël, L., … Schnittger, S. (2016). Gain of chromosome 21 or amplification of
chromosome arm 21q is one mechanism for increased ERG expression in acute myeloid leukemia. Genes, Chromosomes and Cancer, 55(2), 148–
157. https://doi.org/10.1002/gcc.22321
57. Mantovani, G., Lania, A. G., & Spada, A. (2010). GNAS imprinting and pituitary tumors. Molecular and Cellular Endocrinology, 326(1–2), 15–18.
https://doi.org/10.1016/J.MCE.2010.04.009
58. Riminucci, M., Collins, M. T., Lala, R., Corsi, A., Matarazzo, P., Gehron Robey, P., & Bianco, P. (2002). An R201H activating mutation of the GNAS1 (Gsalpha) gene in a corticotroph pituitary adenoma. Molecular Pathology : MP, 55(1), 58–60. Retrieved from
http://www.ncbi.nlm.nih.gov/pubmed/11836449
59. Normann, K. R., Sundaram, A., Oystese, K. A. B., Lekva, T., Eieland, A., Bollerslev, J., & Olarescu, N. C. (2018). Corticotroph pituitary adenomas: the functioning vs the silent: a gene expression study comparing differentially expressed genes in the regulation of POMC. Endocrine Abstracts.
https://doi.org/10.1530/endoabs.56.P783
60. Sakaguchi, C., Ashida, K., Kohashi, K., Ohe, K., Fujii, Y., Yano, S., …
Ogawa, Y. (2019). A case of autonomous cortisol secretion in a patient with subclinical Cushing’s syndrome, GNAS mutation, and paradoxical cortisol response to dexamethasone. BMC Endocrine Disorders, 19(1), 13.
https://doi.org/10.1186/s12902-019-0345-8
61. Zhou, Y., Zhang, X., & Klibanski, A. (2014). Genetic and epigenetic mutations of tumor suppressive genes in sporadic pituitary adenoma. Molecular and Cellular Endocrinology, 386(1–2), 16–33.
https://doi.org/10.1016/j.mce.2013.09.006
62. Low, J. S. Y., Chin, Y. M., Mushiroda, T., Kubo, M., Govindasamy, G. K., Pua, K. C., … Ng, C. C. (2016). A Genome Wide Study of Copy Number Variation Associated with Nasopharyngeal Carcinoma in Malaysian Chinese Identifies CNVs at 11q14.3 and 6p21.3 as Candidate Loci. PLOS ONE, 11(1), e0145774. https://doi.org/10.1371/journal.pone.0145774
63. Gupta, S., Johnson, S. H., Vasmatzis, G., Porath, B., Rustin, J. G., Rao, P.,
… Sukov, W. R. (2017). TFEB-VEGFA (6p21.1) co-amplified renal cell carcinoma: a distinct entity with potential implications for clinical
management. Modern Pathology, 30(7), 998–1012.
https://doi.org/10.1038/modpathol.2017.24
64. Stefansson, I. M., Raeder, M., Wik, E., Mannelqvist, M., Kusonmano, K., Knutsvik, G., … Akslen, L. A. (2015). Increased angiogenesis is associated with a 32-gene expression signature and 6p21 amplification in aggressive endometrial cancer. Oncotarget, 6(12), 10634.
https://doi.org/10.18632/ONCOTARGET.3521
65. Fan, X., Paetau, A., Aalto, Y., Välimäki, M., Sane, T., Poranen, A., … Knuutila, S. (2001). Gain of chromosome 3 and loss of 13q are frequent alterations in pituitary adenomas. Cancer Genetics and Cytogenetics, 128(2), 97–103. https://doi.org/10.1016/S0165-4608(01)00398-3
66. Lecoq, A.-L., Stratakis, C. A., Viengchareun, S., Chaligné, R., Tosca, L., Deméocq, V., … Kamenický, P. (2017). Adrenal GIPR expression and chromosome 19q13 microduplications in GIP-dependent Cushing’s syndrome. JCI Insight, 2(18). https://doi.org/10.1172/JCI.INSIGHT.92184 67. Mishima, Y., Terui, Y., Yokoyama, M., Nishimura, N., Kusano, Y., Hirofumi,
Y., … Hatake, K. (2017). Poor Prognosis of CD5 Positive with Non Germinal Center Type of Diffuse Large B Cell Lymphoma Especially Having the
Aberration of 19q13. Blood, 130(Suppl 1). Retrieved from
http://www.bloodjournal.org/content/130/Suppl_1/4153.abstract?sso-checked=true
68. Petre, G., Lorès, P., Sartelet, H., Truffot, A., Poreau, B., Brandeis, S., … Bidart, M. (2018). Genomic duplication in the 19q13.42 imprinted region identified as a new genetic cause of intrauterine growth restriction. Clinical
69. Dao, D. D., Schroeder, W. T., Chao, L. Y., Kikuchi, H., Strong, L. C., Riccardi, V. M., … Saunders, G. F. (1987). Genetic mechanisms of tumor-specific loss of 11p DNA sequences in Wilms tumor. American Journal of Human
Genetics, 41(2), 202–217. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/3039839
70. Pang, J. T., Lloyd, S. E., Wooding, C., Farren, B., Pottinger, B., Harding, B.,
… Taggart, R. T. (1996). Genetic mapping studies of 40 loci and 23 cosmids in chromosome 11p13-11g13, and exclusion of μ-calpain as the multiple endocrine neoplasia type 1 gene. Human Genetics, 97(6), 732–741.
https://doi.org/10.1007/BF02346182
71. Mudduluru, G., Vajkoczy, P., & Allgayer, H. (2010). Myeloid Zinc Finger 1 Induces Migration, Invasion, and In vivo Metastasis through Axl Gene Expression in Solid Cancer. Molecular Cancer Research, 8(2), 159–169.
https://doi.org/10.1158/1541-7786.MCR-09-0326
72. Westphal, D. S., Andres, S., Makowski, C., Meitinger, T., & Hoefele, J.
(2018). MAP2 – A Candidate Gene for Epilepsy, Developmental Delay and Behavioral Abnormalities in a Patient With Microdeletion 2q34. Frontiers in Genetics, 9, 99. https://doi.org/10.3389/fgene.2018.00099
73. Vouri, M., Croucher, D. R., Kennedy, S. P., An, Q., Pilkington, G. J., & Hafizi, S. (2016). Axl-EGFR receptor tyrosine kinase hetero-interaction provides EGFR with access to pro-invasive signalling in cancer cells. Oncogenesis, 5(10), e266–e266. https://doi.org/10.1038/oncsis.2016.66
74. Revach, O.-Y., Sandler, O., Samuels, Y., & Geiger, B. (2018). Cross-talk between the receptor tyrosine kinases AXL and ERBB3 regulates
invadopodia formation in melanoma cells. BioRxiv, 412379.
https://doi.org/10.1101/412379
75. AXL gene - Genetics Home Reference - NIH. (n.d.). Retrieved March 28, 2019, from https://ghr.nlm.nih.gov/gene/AXL
76. Gioia, R., Trégoat, C., Dumas, P.-Y., Lagarde, V., Prouzet-Mauléon, V., Desplat, V., … Pasquet, J.-M. (2015). CBL controls a tyrosine kinase network involving AXL, SYK and LYN in nilotinib-resistant chronic myeloid leukaemia. The Journal of Pathology, 237(1), 14–24.
https://doi.org/10.1002/path.4561
77. Sahm, F., Korshunov, A., Schrimpf, D., Stichel, D., Jones, D. T. W., Capper, D., … von Deimling, A. (2017). Gain of 12p encompassing CCND2 is
associated with gemistocytic histology in IDH mutant astrocytomas. Acta
Neuropathologica, 133(2), 325–327. https://doi.org/10.1007/s00401-016-1657-7
78. Kaushik, A., & Bhartiya, D. (2018). Pluripotent Very Small Embryonic-Like Stem Cells in Adult Testes – An Alternate Premise to Explain Testicular Germ Cell Tumors. Stem Cell Reviews and Reports, 14(6), 793–800.
https://doi.org/10.1007/s12015-018-9848-3
79. Parker, B. C., & Zhang, W. (2013). Fusion genes in solid tumors: an emerging target for cancer diagnosis and treatment. Chinese Journal of Cancer, 32(11), 594–603. https://doi.org/10.5732/cjc.013.10178
80. Nassif, N. A., Tseng, W., Borges, C., Chen, P., & Eisenberg, B. (2016).
Recent advances in the management of liposarcoma. F1000Research, 5, 2907. https://doi.org/10.12688/f1000research.10050.1
81. Rohen, C., Caselitz, J., Stern, C., Wanschura, S., Schoenmakers, E. F. P.
M., Van de Ven, W. J. M., … Bullerdiek, J. (1995). A hamartoma of the breast with an aberration of 12q mapped to the MAR region by fluorescence in situ hybridization. Cancer Genetics and Cytogenetics, 84(1), 82–84.
https://doi.org/10.1016/0165-4608(95)00060-7
82. Su, W. T., Alaminos, M., Mora, J., Cheung, N.-K., La Quaglia, M. P., &
Gerald, W. L. (2004). Positional gene expression analysis identifies 12q overexpression and amplification in a subset of neuroblastomas. Cancer Genetics and Cytogenetics, 154(2), 131–137.
https://doi.org/10.1016/J.CANCERGENCYTO.2004.02.009
83. Vlotides, G., Cooper, O., Chen, Y.-H., Ren, S.-G., Greenman, Y., & Melmed, S. (2009). Heregulin regulates prolactinoma gene expression. Cancer Research, 69(10), 4209–4216. https://doi.org/10.1158/0008-5472.CAN-08-4934
84. Lampichler, K., Ferrer, P., Vila, G., Lutz, M. I., Wolf, F., Knosp, E., …
Baumgartner-Parzer, S. (2015). The role of proto-oncogene GLI1 in pituitary adenoma formation and cell survival regulation. Endocrine-Related Cancer, 22(5), 793–803. https://doi.org/10.1530/ERC-15-0109
85. Xu, F., Flowers, S., & Moran, E. (2012). Essential Role of ARID2 Protein-containing SWI/SNF Complex in Tissue-specific Gene Expression. The Journal of Biological Chemistry, 287(7), 5033.
https://doi.org/10.1074/JBC.M111.279968
86. Roberts, C. W. M., & Orkin, S. H. (2004). The SWI/SNF complex — chromatin and cancer. Nature Reviews Cancer, 4(2), 133–142.
https://doi.org/10.1038/nrc1273
87. Suliman, M., Royds, J., Cullen, D., Timperley, W., Powell, T., Battersby, R., &
Jones, T. H. (2001). Mdm2 and the p53 pathway in human pituitary adenomas. Clinical Endocrinology, 54(3), 317–325.
https://doi.org/10.1046/j.1365-2265.2001.01195.x
88. Patel, B. K. R., Keck, C. L., O’Leary, R. S., Popescu, N. C., & LaRochelle, W.
J. (1998). Localization of the Human Stat6 Gene to Chromosome 12q13.3–
q14.1, a Region Implicated in Multiple Solid Tumors. Genomics, 52(2), 192–
200. https://doi.org/10.1006/GENO.1998.5436
89. Simbolo, M., Mafficini, A., Sikora, K. O., Fassan, M., Barbi, S., Corbo, V., … Scarpa, A. (2017). Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT , RB1 , MEN1 and KMT2D. The Journal of Pathology, 241(4), 488–500.
https://doi.org/10.1002/path.4853
90. Consortium, E. N. I. G. through M.-A. (ENIGMA), Bis, J. C., DeCarli, C., Smith, A. V., Lijn, F. van der, Crivello, F., … Seshadri, S. (2012). Common variants at 12q14 and 12q24 are associated with hippocampal volume.
Nature Genetics, 44(5), 545–551. https://doi.org/10.1038/ng.2237
91. Gubert, C., Andrejew, R., Jacintho Moritz, C. E., Dietrich, F., Vasconcelos-Moreno, M. P., dos Santos, B. T. M. Q., … Battastini, A. M. O. (2019).
Bipolar disorder and 1513A>C P2RX7 polymorphism frequency.
Neuroscience Letters, 694, 143–147.
https://doi.org/10.1016/J.NEULET.2018.11.055
92. Sprooten, E., Gupta, C. N., Knowles, E. E. M., McKay, D. R., Mathias, S. R., Curran, J. E., … Glahn, D. C. (2015). Genome-wide significant linkage of schizophrenia-related neuroanatomical trait to 12q24. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 168(8), 678–686.
https://doi.org/10.1002/ajmg.b.32360
93. Smyth, D. J., Plagnol, V., Walker, N. M., Cooper, J. D., Downes, K., Yang, J.
H. M., … Todd, J. A. (2008). Shared and Distinct Genetic Variants in Type 1 Diabetes and Celiac Disease. New England Journal of Medicine, 359(26), 2767–2777. https://doi.org/10.1056/NEJMoa0807917
94. Attiyeh, E. F., London, W. B., Mossé, Y. P., Wang, Q., Winter, C., Khazi, D.,
… Children’s Oncology Group. (2005). Chromosome 1p and 11q Deletions and Outcome in Neuroblastoma. New England Journal of Medicine, 353(21), 2243–2253. https://doi.org/10.1056/NEJMoa052399
95. Patel, J. P., Gönen, M., Figueroa, M. E., Fernandez, H., Sun, Z., Racevskis, J., … Levine, R. L. (2012). Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. The New England Journal of Medicine, 366(12), 1079–1089. https://doi.org/10.1056/NEJMoa1112304
96. Danilova, N., Kumagai, A., & Lin, J. (2010). p53 upregulation is a frequent response to deficiency of cell-essential genes. PloS One, 5(12), e15938.
https://doi.org/10.1371/journal.pone.0015938
97. Mete, O., Ezzat, S., & Asa, S. L. (2012). Biomarkers of aggressive pituitary adenomas. Journal of Molecular Endocrinology. https://doi.org/10.1530/jme-12-0113
98. Wierinckx, A., Roche, M., Raverot, G., Legras-Lachuer, C., Croze, S., Nazaret, N., … Lachuer, J. (2011). Integrated Genomic Profiling Identifies Loss of Chromosome 11p Impacting Transcriptomic Activity in Aggressive Pituitary PRL Tumors. Brain Pathology, 21(5), no-no.
https://doi.org/10.1111/j.1750-3639.2011.00476.x
99. Salian-Mehta, S., Xu, M., Knox, A. J., Plummer, L., Slavov, D., Taylor, M., … Wierman, M. E. (2014). Functional Consequences of AXL Sequence
Variants in Hypogonadotropic Hypogonadism. The Journal of Clinical Endocrinology & Metabolism, 99(4), 1452–1460.
https://doi.org/10.1210/jc.2013-3426
100. Zahedi, A., Booth, G. L., Smyth, H. S., Farrell, W. E., Clayton, R. N., Asa, S.
L., & Ezzat, S. (2001). Distinct clonal composition of primary and metastatic adrencorticotrophic hormone-producing pituitary carcinoma. Clinical
Endocrinology, 55(4), 549–556. https://doi.org/10.1046/j.1365-2265.2001.01322.x
101. Kimmelman, A. C., Ross, D. A., & Liang, B. C. (1996). Loss of
Heterozygosity of Chromosome 10p in Human Gliomas. Genomics, 34(2), 250–254. https://doi.org/10.1006/GENO.1996.0277
102. Lee, J. J., Sholl, L. M., Lindeman, N. I., Granter, S. R., Laga, A. C.,
Shivdasani, P., … Lian, C. G. (2015). Targeted next-generation sequencing reveals high frequency of mutations in epigenetic regulators across
treatment-naïve patient melanomas. Clinical Epigenetics, 7(1), 59.
https://doi.org/10.1186/s13148-015-0091-3
103. ZHOU, W., MA, C.-X., XING, Y.-Z., & YAN, Z.-Y. (2016). Identification of candidate target genes of pituitary adenomas based on the DNA microarray.
Molecular Medicine Reports, 13(3), 2182–2186.
https://doi.org/10.3892/mmr.2016.4785
CURRICULUM VITAE